Details for New Drug Application (NDA): 019972

✉ Email this page to a colleague

NDA 019972 describes OCUPRESS, which is a drug marketed by Novartis and is included in one NDA. Additional details are available on the OCUPRESS profile page.

The generic ingredient in OCUPRESS is carteolol hydrochloride. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the carteolol hydrochloride profile page.

Summary for 019972

Tradename:	OCUPRESS
Applicant:	Novartis
Ingredient:	carteolol hydrochloride
Patents:	0

Medical Subject Heading (MeSH) Categories for 019972

Adrenergic beta-Antagonists
Anti-Arrhythmia Agents
Antihypertensive Agents
Sympatholytics

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	SOLUTION/DROPS;OPHTHALMIC			Strength	1% Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons
Approval Date:	May 23, 1990	TE:		RLD:	Yes

Expired US Patents for NDA 019972

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	OCUPRESS	carteolol hydrochloride	SOLUTION/DROPS;OPHTHALMIC	019972-001	May 23, 1990	⤷ Start Trial	⤷ Start Trial
Novartis	OCUPRESS	carteolol hydrochloride	SOLUTION/DROPS;OPHTHALMIC	019972-001	May 23, 1990	⤷ Start Trial	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.